Literature DB >> 29211358

Chest HRCT findings in patients with primary Sjögren's syndrome.

Agata Sebastian1, Maria Misterska-Skóra1, Jurand Silicki2, Maciej Sebastian3, Piotr Wiland1.   

Abstract

BACKGROUND: Pulmonary manifestations (PMs) in primary Sjögren's syndrome (pSS) are among the most frequent extraglandular complications, with reported prevalence varying widely (9-75%), depending on the methods of detection.
OBJECTIVES: The aim of this study was to assess the incidence of PMs in pSS and to determine the factors predisposing to the occurrence of this complication.
MATERIAL AND METHODS: The study group consisted of 68 patients with pSS. Among the patients who were possibly affected by PMs, chest High Resolution Computed Tomography (HRCT) was performed.
RESULTS: In the group of all patients afflicted with pSS, 30 people indicated the need to expand medical imaging via chest HRCT scan. (The most frequent reason, in 80%, was persistent, dry cough periodically waking up patients at night). The chest HRCT scan revealed lung tissue changes in the course of 29% of all examined patients (of 68). No correlation was found between the occurrence of HRCT changes and the age of patients (p = 0.8), increased CRP > 5 mg/1 (p = 0.1) or ESR > 20 mm/h (p = 0.9), focus score (p = 0.8), leucopenia (p = 0.5), RF value (p = 0.3), gamma globulin value (p = 0.5), intensity of eye and oral cavity dryness (p = 0.6; 0.3) and smoking cigarettes. Additionally, no correlation was found between more frequent occurrences of antibodies anti-SSA, anti-SSB or anti-Ro52 and HRCT changes (p = 0.3; 0.07; 0.4). Pertaining to the clinical signs, HRCT changes occurred more often only in patients suffering from peripheral arthritis (p < 0.01).
CONCLUSIONS: PM is a frequent symptom of pSS. A factor predisposing to the development of changes in the respiratory system was not found. Changes in HRCT occur more frequently in patients with peripheral arthritis.

Entities:  

Keywords:  chest HRCT; primary Sjogren’s syndrome; pulmonary manifestation

Mesh:

Substances:

Year:  2017        PMID: 29211358     DOI: 10.17219/acem/68978

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  4 in total

1.  Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian Society of Rheumatology (articular, pulmonary and renal).

Authors:  Virginia Fernandes Moça Trevisani; Alisson Pugliesi; Sandra Gofinet Pasoto; Maria Lucia Lemos Lopes; Lissiane Karine Noronha Guedes; Samira Tatiyama Miyamoto; Marilena Leal Mesquita Silvestre Fernandes; Sonia Cristina de Magalhães Souza Fialho; Aysa César Pinheiro; Laura Caldas Dos Santos; Simone Appenzeller; Tania Fidelix; Sandra Lúcia Euzébio Ribeiro; Danielle Christinne Soares Egypto de Brito; Tatiana Nayara Libório-Kimura; Maria Carmen Lopes Ferreira Silva Santos; Diego Ustárroz Cantali; Juliana D'Agostino Gennari; Vinicius Tassoni Civile; Ana Carolina Pereira Nunes Pinto; César Ramos Rocha-Filho; Fabiola Reis Oliveira; Aline Pereira da Rocha; Valeria Valim
Journal:  Adv Rheumatol       Date:  2022-06-01

2.  A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren's syndrome-related interstitial lung disease in a Chinese population.

Authors:  Xin Dong; Junfei Zhou; Xiaojuan Guo; Yifan Li; Yuetong Xu; Qiang Fu; Yong Lu; Yi Zheng
Journal:  Clin Rheumatol       Date:  2018-09-22       Impact factor: 2.980

3.  How to Distinguish Patients with pSS among Individuals with Dryness without Invasive Diagnostic Studies.

Authors:  Agata Sebastian; Maciej Sebastian; Maria Misterska-Skóra; Patryk Woytala; Katarzyna Jakuszko; Piotr Wiland
Journal:  J Immunol Res       Date:  2018-05-02       Impact factor: 4.818

4.  Quantitative assessment of interstitial lung disease in Sjögren's syndrome.

Authors:  Pablo Guisado-Vasco; Mario Silva; Miguel Angel Duarte-Millán; Gianluca Sambataro; Chiara Bertolazzi; Mauro Pavone; Isabel Martín-Garrido; Oriol Martín-Segarra; José Manuel Luque-Pinilla; Daniele Santilli; Domenico Sambataro; Sebastiano E Torrisi; Ada Vancheri; Marwin Gutiérrez; Mayra Mejia; Stefano Palmucci; Flavio Mozzani; Jorge Rojas-Serrano; Carlo Vanchieri; Nicola Sverzellati; Alarico Ariani
Journal:  PLoS One       Date:  2019-11-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.